

Approved



Central Asia Region
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		514,727		514,727	0	514,727
USAID		2,458,987	1,000,000	3,458,987	3,449,871	6,908,858
HHS/CDC	505,625	7,700,790		8,206,415	170,000	8,376,415
Total	505,625	10,674,504	1,000,000	12,180,129	3,619,871	15,800,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency			On Hold Amount	Total
	State	HHS/CDC	USAID		
HBHC		1,059,060	772,871	0	1,831,931
HKID		0		0	0
HLAB		1,602,633		0	1,602,633
HMBL		0		0	0
HMIN		0		0	0
HTXD		25,605	415	0	26,020
HTXS		1,578,498	10,796	0	1,589,294
HVAB		0		0	0
HVCT		378,987	150,784	0	529,771
HVMS	514,727	1,471,032	607,673	0	2,593,432
HVOP		0	332	0	332
HVSI		652,191	159,295	0	811,486
HVTB		23,228	56,548	0	79,776
IDUP		1,346,594	1,056,886	0	2,403,480
MTCT		0		0	0

Approved



OHSS		68,587	643,387	0	711,974
PDCS		0		0	0
PDTX		0		0	0
	514,727	8,206,415	3,458,987	0	12,180,129



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	1,609,573	0
HVTB	0	0
Total Technical Area Planned Funding:	1,609,573	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,342,901	0
HVSI	611,966	0
OHSS	620,000	0
Total Technical Area Planned Funding:	2,574,867	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	367,843	0
IDUP	2,103,388	0
Total Technical Area Planned Funding:	2,471,231	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	1,371,817	0
Total Technical Area Planned Funding:	1,371,817	0

Approved



Technical Area Summary Indicators and Targets

Kazakhstan

Indicator Number	Label	2017
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	155
	Sex: Male	111
	Sex: Female	44
	Sum of Sex disaggregates	155
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	775
	Total estimated number of key population in the catchment area	18,500
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with	



	<p>individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	



	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>122</p>
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>53</p>
	<p>By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>600</p>
	<p>By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)</p>	
	<p>By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)</p>	
	<p>By key population type: Transgender who are sex workers</p>	



	(Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	15,005
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	3,495
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturning	



	beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,813
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex:		



	Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	600
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+	



	Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	30
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	600
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community)	



	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by	



	Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	



	Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	283,200
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female		
Test Result by Age and Sex: Positive: 15-19 Female		



	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	84,960
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15	0



	Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	198,240
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	0
	Test Result by Aggregated Age and Sex: Positive 15+ Male	274
	Test Result by Aggregated Age and Sex: Positive <15 Female	0
	Test Result by Aggregated Age and Sex: Positive 15+ Female	201
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	



	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	11,198
	Service Delivery Point (Facility): Outpatient	26,131
	Service Delivery Point (Facility): Pediatric	0
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	144,226
	Service Delivery Point (Facility): VCT	4,954
	Service Delivery Point (Facility): VMMC	0
	Service Delivery Point (Facility): PMTCT	92,137
	Service Delivery Point (Facility): TB Clinics	3,819
	Service Delivery Point (Facility): Index testing	735



	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	



	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,608
	Screened for TB by Age/Sex:<15 Male	0
	Screened for TB by Age/Sex: 15+ Male	1,722
	Screened for TB by Age/Sex:<15 Female	0
	Screened for TB by Age/Sex: 15+ Female	886
	Screen Result: Screened Positive for TB	184
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	130
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	117
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	13



	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,608
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	0
	Aggregated Age/Sex: 15+ Male	1,722
	Aggregated Age/Sex: <15 Female	0
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	886
	Sum of Aggregated Age/Sex <15	0
	Sum of Aggregated Age/Sex 15+	2,608
	Sum of Aggregated Age/Sex disaggregates	2,608
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
Age/Sex: 25-49 Female		
Age/Sex: 50+ Female		



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,622
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	0
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,072
	Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	0	
Aggregated Grouping by Age/Sex: 15+ Female	550	
Sum of Aggregated Age/Sex disaggregates	1,622	



	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,619
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,798
	Numerator: Indication: Routine	1,457
	Numerator: Indication: Targeted	162
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication:	



	1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication:	



	50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	1,619
	Denominator: Indication: Targeted	179
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by	



	Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex:	0



	<15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	1,133
	Numerator Aggregated Age/Sex: <15 Female	0
	Numerator Aggregated Age/Sex: 15+ Female	486
	Denominator Aggregated Age/Sex: <15 Male	0
	Denominator Aggregated Age/Sex: 15+ Male	1,258
	Denominator Aggregated Age/Sex: <15 Female	0
	Denominator Aggregated Age/Sex: 15+ Female	540
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	479
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	600
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still	



	alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on	



	treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated	



	<p>ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and</p>	



	those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at	



	12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on	319



	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	160
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	398
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0

Approved



	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
--	--	-----

Approved



Technical Area Summary Indicators and Targets

Kyrgyzstan

(No data provided.)

Technical Area Summary Indicators and Targets

Tajikistan

Indicator Number	Label	2017
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	810
	Sex: Male	735
	Sex: Female	75
	Sum of Sex disaggregates	810
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0
	Sex: Female	0
	Sex: Male	0
	Sum of Sex Disaggregates	0
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group	8,373



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
	Total estimated number of key population in the catchment area	4,485
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that	



	are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,552
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	621
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,200
	By key population type: Men who have sex with men who are sex	



	workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	3,590
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	895
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the	



	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	22,182
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male		



	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	



Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,319
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,863
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	
Test Result by Aggregated Age and Sex: Positive 15+ Male	1,570
Test Result by Aggregated Age and Sex: Positive <15 Female	
Test Result by Aggregated Age and Sex: Positive 15+ Female	337
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point (Community): Index testing	
Service Delivery Point (Community): Homebased testing	



	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	19,626
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	456
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	1,900
	Service Delivery Point (Facility): VMMC	



	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	



	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	148,680
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex:		



	Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex:	



	Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	44,604
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	104,076
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	0
	Test Result by Aggregated Age and Sex: Positive 15+ Male	413
	Test Result by Aggregated Age and Sex: Positive <15 Female	0
	Test Result by Aggregated Age and Sex: Positive 15+ Female	314
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	



	(Community): Index testing	
	Service Delivery Point	
	(Community): Homebased testing	
	Service Delivery Point	
	(Community): Mobile testing	
	Service Delivery Point	
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	5,761
	Service Delivery Point (Facility): Outpatient	13,443
	Service Delivery Point (Facility): Pediatric	0
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	66,875
	Service Delivery Point (Facility):	1,187



VCT	
Service Delivery Point (Facility): VMMC	0
Service Delivery Point (Facility): PMTCT	58,068
Service Delivery Point (Facility): TB Clinics	2,349
Service Delivery Point (Facility): Index testing	997
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,323
	Screened for TB by Age/Sex:<15 Male	0
	Screened for TB by Age/Sex: 15+ Male	1,993
	Screened for TB by Age/Sex:<15 Female	0
	Screened for TB by Age/Sex: 15+ Female	1,330
	Screen Result: Screened Positive for TB	132
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+	



	Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	93
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	85
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,323
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	0
	Aggregated Age/Sex: 15+ Male	1,993
	Aggregated Age/Sex: <15 Female	0
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,330
	Sum of Aggregated Age/Sex <15	0
	Sum of Aggregated Age/Sex 15+	3,323
	Sum of Aggregated Age/Sex disaggregates	3,323
	Age/Sex: <1	
	Age/Sex: <1-9	
Age/Sex: 10-14 Male		
Age/Sex: 10-14 Female		
Aggregated Age/Sex: 1-14 Male		



	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,112
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	0
	Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	1,267	



	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	0
	Aggregated Grouping by Age/Sex: 15+ Female	845
	Sum of Aggregated Age/Sex disaggregates	2,112
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,633
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,814
	Numerator: Indication: Routine	1,469
	Numerator: Indication: Targeted	164
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication:	



	Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication:	



	10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Female Routine	
	Denominator: Indication: Routine	1,633
	Denominator: Indication: Targeted	181
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by	



	Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	0
	Numerator Aggregated Age/Sex: 15+ Male	1,143
	Numerator Aggregated Age/Sex: <15 Female	0
	Numerator Aggregated Age/Sex: 15+ Female	490
	Denominator Aggregated Age/Sex: <15 Male	0
	Denominator Aggregated Age/Sex: 15+ Male	1,269
	Denominator Aggregated Age/Sex: <15 Female	0
	Denominator Aggregated Age/Sex: 15+ Female	545
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	233
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	291



	who have died, those who have stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	



	initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of	



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have</p>	



	stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status:	



	Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	140
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	156



	those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	135

Approved



Technical Area Summary Indicators and Targets

Turkmenistan

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

Uzbekistan

(No data provided.)

Technical Area Summary Indicators and Targets

Central Asia Region

Indicator Number	Label	2017
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	965
	Sex: Male	846
	Sex: Female	119
	Sum of Sex disaggregates	965
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0
	Sex: Female	0
	Sex: Male	0
	Sum of Sex Disaggregates	0
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group	9,148



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
	Total estimated number of key population in the catchment area	22,985
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that	



	are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,674
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	674
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,800
	By key population type: Men who have sex with men who are sex	



	workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	18,595
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	4,390
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the	



	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	26,995
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male		



	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	



Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,919
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,863
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	
Test Result by Aggregated Age and Sex: Positive 15+ Male	1,600
Test Result by Aggregated Age and Sex: Positive <15 Female	
Test Result by Aggregated Age and Sex: Positive 15+ Female	337
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point (Community): Index testing	
Service Delivery Point (Community): Homebased testing	



	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	20,226
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	456
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	1,900
	Service Delivery Point (Facility): VMMC	



	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	



	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	431,880
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex:	



	Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex:	



	Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	129,564
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	302,316
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	0
	Test Result by Aggregated Age and Sex: Positive 15+ Male	687
	Test Result by Aggregated Age and Sex: Positive <15 Female	0
	Test Result by Aggregated Age and Sex: Positive 15+ Female	515
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	



	(Community): Index testing	
	Service Delivery Point	
	(Community): Homebased testing	
	Service Delivery Point	
	(Community): Mobile testing	
	Service Delivery Point	
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	16,959
	Service Delivery Point (Facility): Outpatient	39,574
	Service Delivery Point (Facility): Pediatric	0
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	211,101
	Service Delivery Point (Facility):	6,141



VCT	
Service Delivery Point (Facility): VMMC	0
Service Delivery Point (Facility): PMTCT	150,205
Service Delivery Point (Facility): TB Clinics	6,168
Service Delivery Point (Facility): Index testing	1,732
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,931
	Screened for TB by Age/Sex:<15 Male	0
	Screened for TB by Age/Sex: 15+ Male	3,715
	Screened for TB by Age/Sex:<15 Female	0
	Screened for TB by Age/Sex: 15+ Female	2,216
	Screen Result: Screened Positive for TB	316
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+	



	Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	223
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	202
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	21
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,931
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	0
	Aggregated Age/Sex: 15+ Male	3,715
	Aggregated Age/Sex: <15 Female	0
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	2,216
	Sum of Aggregated Age/Sex <15	0
	Sum of Aggregated Age/Sex 15+	5,931
	Sum of Aggregated Age/Sex disaggregates	5,931
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
Age/Sex: 10-14 Female		
Aggregated Age/Sex: 1-14 Male		



	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,734
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	0
Aggregated Grouping by Age/Sex: 1-14 Male		
Aggregated Grouping by Age/Sex: 15+ Male	2,339	



	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	0
	Aggregated Grouping by Age/Sex: 15+ Female	1,395
	Sum of Aggregated Age/Sex disaggregates	3,734
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,252
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,612
	Numerator: Indication: Routine	2,926
	Numerator: Indication: Targeted	326
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication:	



	Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication:	



	10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Female Routine	
	Denominator: Indication: Routine	3,252
	Denominator: Indication: Targeted	360
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by	



	Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	0
	Numerator Aggregated Age/Sex: 15+ Male	2,276
	Numerator Aggregated Age/Sex: <15 Female	0
	Numerator Aggregated Age/Sex: 15+ Female	976
	Denominator Aggregated Age/Sex: <15 Male	0
	Denominator Aggregated Age/Sex: 15+ Male	2,527
	Denominator Aggregated Age/Sex: <15 Female	0
	Denominator Aggregated Age/Sex: 15+ Female	1,085
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	712
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	891



	who have died, those who have stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	



	initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	



	stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status:	



	Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	459
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	253
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	554



	those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	337



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
12799	Ministry of Health/Republican AIDS Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	428,000
12812	Ministry of Health/Republican Narcology Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	262,895
12889	Ministry of Health/Republican AIDS Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	364,901
13970	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	510,000



17050	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	250,000
17051	AIDS Foundation East, West	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	900,000
17067	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
17565	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,397,092
17776	Ministry of Health/Republican Narcology Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	224,600
17777	Ministry of Health/Republican Narcology Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	85,000
17813	FHI 360	NGO	U.S. Agency for International Development	GHP-State	350,000
18124	United Nations Office on Drug	Multi-lateral Agency	U.S. Agency for International	GHP-State	350,000



	and Crime (UNODC)		Development		
18155	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	400,000
18196	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	250,000
18226	Republican AIDS Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	255,000



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 12799	Mechanism Name: Support to Ministry of Health/Republican AIDS Center of the Republic of Tajikistan
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican AIDS Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Tajikistan	428,000

Total All Funding Sources: 428,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 428,000		
Managing Country	Funding Source	Funding Amount
Tajikistan	GHP-State	428,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12799
Mechanism Name: Support to Ministry of Health/Republican AIDS Center of the Republic of



Prime Partner Name: Tajikistan			
Ministry of Health/Republican AIDS Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	115,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	117,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	71,000	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Tajikistan	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,900
Tajikistan	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,562
Tajikistan	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	338
Tajikistan	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,900
Tajikistan	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,900
Tajikistan	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	152
Tajikistan	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	17



Tajikistan	HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,900
------------	-------------	--	-------

Implementing Mechanism Details

Mechanism ID: 12812	Mechanism Name: Support to Ministry of Health/Republican Narcology Center of the Kyrgyz Republic
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican Narcology Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Kyrgyzstan	0

Total All Funding Sources: 262,895		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 262,895		
Managing Country	Funding Source	Funding Amount
Kyrgyzstan	GHP-State	262,895

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12812
Mechanism Name:	Support to Ministry of Health/Republican Narcology Center of the
Prime Partner Name:	Kyrgyz Republic



Ministry of Health/Republican Narcology Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,279	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	27,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	185,216	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12889	Mechanism Name: Support to Ministry of Health/Republican AIDS Center of the Republic of Kazakhstan
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican AIDS Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	364,901

Total All Funding Sources: 364,901		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 364,901		
Managing Country	Funding Source	Funding Amount



Kazakhstan	GHP-State	364,901
------------	-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12889		
Mechanism Name:	Support to Ministry of Health/Republican AIDS Center of the Republic of Kazakhstan		
Prime Partner Name:	Ministry of Health/Republican AIDS Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	174,901	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	175,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13970	Mechanism Name: CLSI (under the former Lab Coalition mechanism)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	70,000
Kyrgyzstan	225,000
Tajikistan	215,000

Total All Funding Sources: 510,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 510,000		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	70,000
Kyrgyzstan	GHP-State	225,000
Tajikistan	GHP-State	215,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13970		
Mechanism Name:	CLSI (under the former Lab Coalition mechanism)		
Prime Partner Name:	Clinical and Laboratory Standards Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	510,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17050	Mechanism Name: UNAIDS
Funding Agency: USAID	Procurement Type: Umbrella Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	87,500
Kyrgyzstan	75,000
Tajikistan	87,500

Total All Funding Sources: 250,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 250,000		
Managing Country	Funding Source	Funding Amount
Kyrgyzstan	GHP-State	75,000
Kazakhstan	GHP-State	87,500
Tajikistan	GHP-USAID	87,500

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17050			
Mechanism Name: UNAIDS			
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	75,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17051	Mechanism Name: HIV REACT
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Foundation East, West	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	321,007
Kyrgyzstan	310,007
Tajikistan	268,986

Total All Funding Sources: 900,000		
---	--	--



Applied Pipeline Amount: 200,000		
Total All Funding Sources and Applied Pipeline Amount: 1,100,000		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	100,000
Kazakhstan	GHP-USAID	800,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	75,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 17051			
Mechanism Name: HIV REACT			
Prime Partner Name: AIDS Foundation East, West			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	270,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	450,000	0



Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Kazakhstan	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	600
Kazakhstan	KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	600
Kazakhstan	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	600
Kazakhstan	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	600
Kazakhstan	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	600
Kazakhstan	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	600
Kazakhstan	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	30
Kazakhstan	HTC_TST_DSD	Service Delivery Point (Community): Other	600
Tajikistan	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,200
Tajikistan	KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual	2,200



		and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
Tajikistan	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,200
Tajikistan	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,200
Tajikistan	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,200
Tajikistan	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,200
Tajikistan	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	110
Tajikistan	HTC_TST_DSD	Service Delivery Point (Community): Other	2,000

Implementing Mechanism Details

Mechanism ID: 17067	Mechanism Name: HIV Flagship Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 2,560,857		
Total All Funding Sources and Applied Pipeline Amount: 2,560,857		
Managing Country	Funding Source	Funding Amount



Kazakhstan	GHP-State	0
Tajikistan	GHP-State	0
Kyrgyzstan	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17067			
Mechanism Name: HIV Flagship Project			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0

Implementing Mechanism Indicator Information



OU	Indicator Number	Label	2017
Kazakhstan	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,213
Tajikistan	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,224
Tajikistan	KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,703
Tajikistan	KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	521
Tajikistan	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,626
Tajikistan	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,161
Tajikistan	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,465
Tajikistan	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,626
Tajikistan	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	17,626
Tajikistan	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,270



Tajikistan	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	315
Tajikistan	HTC_TST_DSD	Service Delivery Point (Community): Other	17,626

Implementing Mechanism Details

Mechanism ID: 17565	Mechanism Name: Technical Assistance Services to Countries Supported by PEPFAR and the Global Fund
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	1,004,128
Kyrgyzstan	1,171,482
Tajikistan	1,221,482

Total All Funding Sources: 3,397,092		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 3,397,092		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	1,004,128
Kyrgyzstan	GHP-State	1,171,482
Tajikistan	GHP-State	1,221,482

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17565		
Mechanism Name:	Technical Assistance Services to Countries Supported by PEPFAR and the Global Fund		
Prime Partner Name:	Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	767,294	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	428,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	366,966	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	133,443	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	700,572	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,000,817	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Kazakhstan	KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at	155



		least 6 months	
Kazakhstan	KP_MAT_DSD	Sex: Male	111
Kazakhstan	KP_MAT_DSD	Sex: Female	44
Kazakhstan	KP_MAT_DSD	Sum of Sex disaggregates	155
Kazakhstan	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	175
Kazakhstan	KP_PREV_DSD	Total estimated number of key population in the catchment area	18,500
Kazakhstan	KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	122
Kazakhstan	KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	53
Kazakhstan	KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	15,005
Kazakhstan	KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	3,495
Kazakhstan	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test	283,200



		results during the past 12 months	
Kazakhstan	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
Kazakhstan	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	84,960
Kazakhstan	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
Kazakhstan	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	198,240
Kazakhstan	HTC_TST_TA	Sum of Aggregated Age/Sex <15	0
Kazakhstan	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	283,200
Kazakhstan	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	283,200
Kazakhstan	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	0
Kazakhstan	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	274
Kazakhstan	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	0
Kazakhstan	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	201
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): Inpatient	11,198
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): Outpatient	26,131
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): Other PITC	144,226
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): VCT	4,954
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): PMTCT	92,137
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	3,819
Kazakhstan	HTC_TST_TA	Service Delivery Point (Facility): Index testing	735
Kazakhstan	TB_SCREENDX_DS	The number of PLHIV who were screened	2,608

	D	for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	
Kazakhstan	TB_SCREENDX_DS D	Screened for TB by Age/Sex:<15 Male	0
Kazakhstan	TB_SCREENDX_DS D	Screened for TB by Age/Sex: 15+ Male	1,722
Kazakhstan	TB_SCREENDX_DS D	Screened for TB by Age/Sex:<15 Female	0
Kazakhstan	TB_SCREENDX_DS D	Screened for TB by Age/Sex: 15+ Female	886
Kazakhstan	TB_SCREENDX_DS D	Screen Result: Screened Positive for TB	184
Kazakhstan	TB_SCREENDX_DS D	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	130
Kazakhstan	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	117
Kazakhstan	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	13
Kazakhstan	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
Kazakhstan	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,608
Kazakhstan	TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
Kazakhstan	TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,722
Kazakhstan	TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
Kazakhstan	TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	886
Kazakhstan	TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
Kazakhstan	TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,608
Kazakhstan	TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,608
Kazakhstan	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,622
Kazakhstan	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0



Kazakhstan	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,072
Kazakhstan	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
Kazakhstan	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	550
Kazakhstan	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,622
Kazakhstan	TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,619
Kazakhstan	TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,798
Kazakhstan	TX_PVLS_DSD	Numerator: Indication: Routine	1,457
Kazakhstan	TX_PVLS_DSD	Numerator: Indication: Targeted	162
Kazakhstan	TX_PVLS_DSD	Denominator: Indication: Routine	1,619
Kazakhstan	TX_PVLS_DSD	Denominator: Indication: Targeted	179
Kazakhstan	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	0
Kazakhstan	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,133
Kazakhstan	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0
Kazakhstan	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	486
Kazakhstan	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	0
Kazakhstan	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,258
Kazakhstan	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
Kazakhstan	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+	540



		Female	
Kazakhstan	TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	479
Kazakhstan	TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	600
Kazakhstan	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
Kazakhstan	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	319
Kazakhstan	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
Kazakhstan	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	160
Kazakhstan	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
Kazakhstan	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months	398

		prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
Kazakhstan	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
Kazakhstan	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
Tajikistan	KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	430
Tajikistan	KP_MAT_DSD	Sex: Male	406
Tajikistan	KP_MAT_DSD	Sex: Female	24
Tajikistan	KP_MAT_DSD	Sum of Sex disaggregates	430
Tajikistan	KP_MAT_TA	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	380
Tajikistan	KP_MAT_TA	Sex: Female	35
Tajikistan	KP_MAT_TA	Sex: Male	345
Tajikistan	KP_MAT_TA	Sum of Sex Disaggregates	380
Tajikistan	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	454

Tajikistan	KP_PREV_DSD	Total estimated number of key population in the catchment area	4,485
Tajikistan	KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	420
Tajikistan	KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	34
Tajikistan	KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	3,590
Tajikistan	KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	895
Tajikistan	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	148,680
Tajikistan	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
Tajikistan	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	44,604
Tajikistan	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
Tajikistan	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	104,076

Tajikistan	HTC_TST_TA	Sum of Aggregated Age/Sex <15	0
Tajikistan	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	148,680
Tajikistan	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	148,680
Tajikistan	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	0
Tajikistan	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	413
Tajikistan	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	0
Tajikistan	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	314
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): Inpatient	5,761
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): Outpatient	13,443
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): Other PITC	66,875
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): VCT	1,187
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): PMTCT	58,068
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,349
Tajikistan	HTC_TST_TA	Service Delivery Point (Facility): Index testing	997
Tajikistan	TB_SCREENDX_DS D	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,323
Tajikistan	TB_SCREENDX_DS D	Screened for TB by Age/Sex:<15 Male	0
Tajikistan	TB_SCREENDX_DS D	Screened for TB by Age/Sex: 15+ Male	1,993
Tajikistan	TB_SCREENDX_DS D	Screened for TB by Age/Sex:<15 Female	0
Tajikistan	TB_SCREENDX_DS	Screened for TB by Age/Sex: 15+ Female	1,330



	D		
Tajikistan	TB_SCREENDX_DS D	Screen Result: Screened Positive for TB	132
Tajikistan	TB_SCREENDX_DS D	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	93
Tajikistan	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	85
Tajikistan	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8
Tajikistan	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
Tajikistan	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,323
Tajikistan	TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
Tajikistan	TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,993
Tajikistan	TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
Tajikistan	TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,330
Tajikistan	TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
Tajikistan	TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,323
Tajikistan	TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,323
Tajikistan	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,112
Tajikistan	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
Tajikistan	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,267
Tajikistan	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
Tajikistan	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	845
Tajikistan	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,112
Tajikistan	TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results	1,633

		(<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
Tajikistan	TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,814
Tajikistan	TX_PVLS_DSD	Numerator: Indication: Routine	1,469
Tajikistan	TX_PVLS_DSD	Numerator: Indication: Targeted	164
Tajikistan	TX_PVLS_DSD	Denominator: Indication: Routine	1,633
Tajikistan	TX_PVLS_DSD	Denominator: Indication: Targeted	181
Tajikistan	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	0
Tajikistan	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,143
Tajikistan	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0
Tajikistan	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	490
Tajikistan	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	0
Tajikistan	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,269
Tajikistan	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
Tajikistan	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	545
Tajikistan	TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	233
Tajikistan	TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	291



Tajikistan	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
Tajikistan	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	140
Tajikistan	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
Tajikistan	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93
Tajikistan	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
Tajikistan	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	156
Tajikistan	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0



		lost to follow-up)	
Tajikistan	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	135

Implementing Mechanism Details

Mechanism ID: 17776	Mechanism Name: Tajikistan - Republican Narcology Center
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican Narcology Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Tajikistan	224,600

Total All Funding Sources: 224,600		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 224,600		
Managing Country	Funding Source	Funding Amount
Tajikistan	GHP-State	224,600

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17776			
Mechanism Name: Tajikistan - Republican Narcology Center			
Prime Partner Name: Ministry of Health/Republican Narcology Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	67,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	157,600	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Tajikistan	KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	380
Tajikistan	KP_MAT_DSD	Sex: Male	329
Tajikistan	KP_MAT_DSD	Sex: Female	51
Tajikistan	KP_MAT_DSD	Sum of Sex disaggregates	380
Tajikistan	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	495
Tajikistan	KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	429



Tajikistan	KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	66
Tajikistan	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	456
Tajikistan	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	396
Tajikistan	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	60
Tajikistan	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	456
Tajikistan	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	456
Tajikistan	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	38
Tajikistan	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	5
Tajikistan	HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	456

Implementing Mechanism Details

Mechanism ID: 17777	Mechanism Name: Kazakhstan - Republican Narcology Center
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican Narcology Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	85,000



Total All Funding Sources: 85,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 85,000		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	85,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17777		
Mechanism Name:	Kazakhstan - Republican Narcology Center		
Prime Partner Name:	Ministry of Health/Republican Narcology Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	85,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17813	Mechanism Name: LINKAGES
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	105,000
Kyrgyzstan	105,000
Tajikistan	140,000

Total All Funding Sources: 350,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 350,000		
Managing Country	Funding Source	Funding Amount
Tajikistan	GHP-State	140,000
Kyrgyzstan	GHP-State	105,000
Kazakhstan	GHP-State	105,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17813		
Mechanism Name:	LINKAGES		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	280,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18124	Mechanism Name: UNODC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	122,500
Kyrgyzstan	105,000
Tajikistan	122,500

Total All Funding Sources: 350,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 350,000		
Managing Country	Funding Source	Funding Amount
Tajikistan	GHP-State	122,500
Kyrgyzstan	GHP-State	105,000
Kazakhstan	GHP-State	122,500

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18124			
Mechanism Name: UNODC			
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	245,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18155		Mechanism Name: LEADER for PLHIV	
Funding Agency: USAID		Procurement Type: Cooperative Agreement	
Prime Partner Name: Futures Group			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	108,000
Kyrgyzstan	148,000
Tajikistan	144,000

Total All Funding Sources: 400,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 400,000		



Managing Country	Funding Source	Funding Amount
Tajikistan	GHP-State	144,000
Kyrgyzstan	GHP-State	148,000
Kazakhstan	GHP-State	108,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,466
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	18155		
Mechanism Name:	LEADER for PLHIV		
Prime Partner Name:	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	280,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	120,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18196	Mechanism Name: Global Health Supply Chain
----------------------------	---



Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	82,500
Kyrgyzstan	82,500
Tajikistan	85,000

Total All Funding Sources: 250,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 250,000		
Managing Country	Funding Source	Funding Amount
Tajikistan	GHP-State	85,000
Kyrgyzstan	GHP-State	82,500
Kazakhstan	GHP-State	82,500

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18196		
Mechanism Name:	Global Health Supply Chain		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Governance and Systems	OHSS	250,000	0
------------------------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18226	Mechanism Name: Republican AIDS Center of the Republic of Kyrgyzstan
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Republican AIDS Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Kyrgyzstan	255,000

Total All Funding Sources: 255,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 255,000		
Managing Country	Funding Source	Funding Amount
Kyrgyzstan	GHP-State	255,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18226			
Mechanism Name: Republican AIDS Center of the Republic of Kyrgyzstan			
Prime Partner Name: Republican AIDS Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	115,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	125,000	0

Implementing Mechanism Indicator Information

(No data provided.)

**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		77,500		0	77,500	77,500
ICASS		274,680		239,850	274,680	514,530
Institutional Contractors				0	0	0



Management Meetings/Professional Development		59,000		0	59,000	59,000
Non-ICASS Administrative Costs		15,000		66,353	15,000	81,353
Staff Program Travel		112,193		80,608	112,193	192,801
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		308,114	112,500	302,203	420,614	722,817
Total	0	846,487	112,500	689,014	958,987	1,648,001

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		461,500		0	461,500	461,500



Computers/IT Services		30,000		0	30,000	30,000
ICASS		585,000		0	585,000	585,000
Non-ICASS Administrative Costs		111,305		170,000	111,305	281,305
Staff Program Travel		360,000		0	360,000	360,000
USG Staff Salaries and Benefits - Internationally Recruited	505,625			0	505,625	505,625
USG Staff Salaries and Benefits - Locally Recruited		625,497		0	625,497	625,497
Total	505,625	2,173,302	0	170,000	2,678,927	2,848,927

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		15,777		0	15,777	15,777
Computers/IT Services		3,000		0	3,000	3,000

Approved



ICASS		28,000		0	28,000	28,000
Management Meetings/Professional Development		5,000		0	5,000	5,000
Non-ICASS Administrative Costs		64,250		0	64,250	64,250
Staff Program Travel		69,000		0	69,000	69,000
USG Staff Salaries and Benefits - Internationally Recruited		280,000		0	280,000	280,000
USG Staff Salaries and Benefits - Locally Recruited		49,700		0	49,700	49,700
Total	0	514,727	0	0	514,727	514,727